NetraMark Holdings Inc. (TSX: AIAI | OTCQB: AINMF | Frankfurt: PF0) announced that Dr. Joseph Geraci, Founder and Chief Scientific and Technical Officer, will participate in the H.C. Wainwright 3rd Annual AI Based Drug Discovery and Development Virtual Conference on October 8–9, 2026. Dr. Geraci will join a panel titled "Design Got Cheap - Where Is the Defensible Moat?", focused on competitive differentiation as artificial intelligence reshapes pharmaceutical development. The appearance gives investors a public forum in which to hear NetraMark's strategic positioning directly from its founder.

Key Points

  • NetraMark Holdings Inc. (TSX: AIAI | OTCQB: AINMF | Frankfurt: PF0) is a Toronto-based clinical intelligence company
  • Dr. Joseph Geraci will participate in a panel discussion at the H.C. Wainwright virtual conference on October 8–9, 2026
  • The panel runs 4:00–5:00 p.m. Eastern Time and is moderated by H.C. Wainwright Managing Director Swayampakula Ramakanth
  • Investors may be watching for commentary on how NetraMark's proprietary NetraAI platform differentiates from competing AI tools

Panel Focus on AI's Defensible Moat in Drug Development

Dr. Geraci will be joined on the panel by Peyton Greenside, CEO and Co-founder of BigHat Biosciences, and Jennifer Bath, CEO of MindWalk AI. The session is designed to address how biotechnology and pharmaceutical companies can sustain competitive advantages as AI tooling becomes more widely accessible and lower cost. The panel's central question — where defensible differentiation lies as design costs fall — is directly relevant to NetraMark's commercial positioning in clinical trial analytics, the announcement suggests.

How NetraAI Targets Small, Heterogeneous Clinical Trial Datasets

NetraMark's proprietary NetraAI platform is engineered to parse small patient datasets into explainable and unexplainable subsets, isolating patient subpopulations that conventional AI methods may obscure through overfitting. The release states the platform seeks to surface insights around treatment response, placebo response, and adverse events — factors that influence trial design and patient selection. According to the company, many competing AI approaches assign every patient to a class, a process the company says can suppress clinically meaningful signals within small trial populations.

Dr. Geraci's Comments on Patient Population Insights

In a statement included in the announcement, Dr. Geraci said that as AI makes it more efficient to generate drug candidates, understanding which patients are most likely to benefit remains a critical challenge. He described NetraMark's approach as allowing the company to extract insights about patient populations that AI generally struggles with, characterising this capability as a defensible moat that can augment broader AI capabilities in drug development. The company did not disclose specific clinical or commercial outcomes tied to this positioning in the announcement.